Fertilis builds hair-width, patented 3D-printed cradles that allow embryos to be cultured in environments that more closely resemble the human body and reduce direct handling by clinicians. The cradles sit on petri dishes so embryos do not need to be picked up during routine transfers and monitoring. The devices are intended to standardize and automate the IVF workflow and can also be used to culture other cell types beyond fertilization. The two-year-old company was founded by reproductive biologist Jeremy Thompson and entrepreneur Marty Gauvin. Fertilis is seeking FDA approval and plans to begin global clinical trials late this year, with an agreement in place to run trials at a fertility clinic in California and discussions underway with partners in Europe and Asia. The new funding will support ongoing scientific development and the company aims to introduce its first commercial product by 2023.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Jan 2022